Michael Lowe

Surgical oncologist, melanoma specialist, researcher, husband, father

[Michael Lowe @MichaelCLoweMD]

@WinshipAtEmory Thrilled to represent the study team of our TIME trial and grateful to our patients and staff who are making this trial possible.

[Michael Lowe @MichaelCLoweMD]

@WinshipAtEmory Join us for an incredible group of speakers to discuss updates in management of melanoma, MCC, SCC, and difficult pigmented lesions @DrSapnaPatel @MarkFariesMD @SuephyC Michael Tetzlaff @UCSFCancer Chris Barker @MSKCancerCenter

[SWOG Cancer Research Network @SWOG]

Results of @SWOG S1801 in @NEJM: Patients w resectable melanoma who got 3 doses of pembrolizumab before surgery & 15 doses after had significantly longer event-free survival than those who got 18 doses after surgery. https://t.co/L3I0N5k8Wj @DrSapnaPatel @MDAndersonNews @UCLAJCCC

[Michael Lowe @MichaelCLoweMD]

@Chrystal_Paulos @WinshipAtEmory @sitcancer Thanks to @gmboland and @sitcancer for the invitation to highlight with @AshleyHolderMD the importance of surgeons in the care of patients with metastatic melanoma @EmorySurgery

[Michael Lowe @MichaelCLoweMD]

Grateful for the tremendous efforts of the study team and our patients (and for the support of great colleagues like @CrisyRoland). What neoadjuvant regimen is the right one?! @WinshipAtEmory

[Christina Roland, MD, MS @CrisyRoland]

@MichaelCLoweMD @EmorySurgery presenting exciting data evaluating pepinimab +/- nivolumab/ipilimimab in patients with resectable melanoma.

[Michael Lowe @MichaelCLoweMD]

Congratulations @DrSapnaPatel and the S1801 study team on an incredible practice-changing effort @WinshipAtEmory @MDAndersonNews

[Michael Lowe @MichaelCLoweMD]

@LesinskiLab @WinshipAtEmory @EmoryUniversity Come join our collaborative multidisciplinary and translational team of outstanding melanoma scientists and clinicians @zach_buchwald @Chrystal_Paulos.

[Michael Lowe @MichaelCLoweMD]

Excited to join my colleagues @TJH0828 @ragikudchadkar and Scott Albert in a thought provoking discussion.

[Society of Surgical Oncology @SocSurgOnc]

Sign up for a new virtual tumor board on April 25. @TJH0828, Scott Albert, MD, @MichaelCLoweMD & Ragini Kudchadkar, MD, will have a case-based discussion on evidence supporting neoadjuvant systemic therapy for surgically resectable #melanoma. Register at https://t.co/gOykSXuqMn.

[Michael Lowe @MichaelCLoweMD]

@SESC_AmSurg Congrats to @RandiSmithMD for her excellent pitch to the sharks. Privileged to moderate with my Research Committee co- chair Jim McLoughlin on behalf of the committee and the @SESC_AmSurg @EmorySurgery

[SESC & The American Surgeon @SESC_AmSurg]

SESC Sharks!

[Winship Cancer Institute of Emory University @WinshipAtEmory]

Emory investigators will receive a total of $955,000 in funding for new research projects from the Morningside Center for Innovative and Affordable Medicine. The six awards include five team projects led by researchers from Winship. ➡️ https://t.co/qeffUtr0re

[Michael Lowe @MichaelCLoweMD]

Proud to represent @emoryhealthcare @WinshipAtEmory and @EmorySurgery throwing out first pitch @Braves tonight.

[Ragini Kudchadkar, MD @ragikudchadkar]

Perfect pitch @MichaelCLoweMD! @Braves @WinshipAtEmory @EmoryHealthcare #SunSafety

[Winship Cancer Institute of Emory University @WinshipAtEmory]

Winship and the @Braves have partnered to promote #sunsafety this summer. Winship surgical oncologist @MichaelCLoweMD will throw out the first pitch at the Braves game this Friday night and remind fans to play it safe in the sun. #EmoryBraves ⚾ https://t.co/ZtsyPneRHu

[Society of Surgical Oncology @SocSurgOnc]

In the latest episode of SurgOnc Today, Richard White, MD, moderates as Nasreen Vohra, MD, reviews updates on local therapies and @MichaelCLoweMD reviews updates on neoadjuvant trials in #melanoma. Listen at https://t.co/INOcYljNDs or subscribe on Apple Podcasts and Spotify.

[Melanoma and Skin Cancer Trials (MASC Trials) @MASC_Trials]

Another significant step forward for MelMarT-II, with 23 more participants recruited last month. A fantastic global effort to improve outcomes for patients with stage II primary #melanoma. More info at https://t.co/tty50uUZqt #clinicaltrials #surgery #cancerresearch

[Michael Lowe @MichaelCLoweMD]

@WinshipAtEmory Great collaboration with @ragikudchadkar

[Winship Cancer Institute of Emory University @WinshipAtEmory]

#ASCO21 | Poster Session | Melanoma/Skin Cancers
"Winship 4851-19: A pilot study of neoadjuvant and adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma"
First Author: Michael Lowe, MD, MA (@MichaelCLoweMD)
➡️ https://t.co/LK6P1KtEXB

[Winship Cancer Institute of Emory University @WinshipAtEmory]

#WinshipClinicalTrial
UCDCCSO034 | Biomarker Analysis of Neoadjuvant Intralesional Therapy in High-Risk Primary #Melanoma: A Multi-Institutional Phase II Study
#melsm ➡️ https://t.co/Y3JDXg5xn4

[Tina J Hieken MD @TJH0828]

Analysis of Head/Neck Melanoma Rx in post-MSLT 2 era from Dr. Baecher @WinshipAtEmory and colleagues from 21 centers #EADO2021 @KristyBroman @MoffittNews @USouthFlorida @tashahughesmd @umichsurgery @leslydossett @jamessunmd @mikejcarr @sloan_kettering @MelanomaAus @OlofssonBagge